Sekar Kathiresan - 28 Jun 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol
VERV
Transactions as of
28 Jun 2024
Net transactions value
+$86,100
Form type
4
Filing time
02 Jul 2024, 07:30:03 UTC
Previous filing
05 Jun 2024
Next filing
04 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $86,100 +30,000 +9.3% $2.87 351,128 28 Jun 2024 Direct F1
holding VERV Common Stock 240,997 28 Jun 2024 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 80,997 28 Jun 2024 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -30,000 -12% $0.000000 215,308 28 Jun 2024 Common Stock 30,000 $2.87 Direct F2
holding VERV Stock Option (right to buy) 160,000 28 Jun 2024 Common Stock 160,000 $2.87 Sekar Kathiresan 2022 Annuity Trust F3
holding VERV Stock Option (right to buy) 200,000 28 Jun 2024 Common Stock 200,000 $2.87 Sekar Kathiresan 2023 Annuity Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2 The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
F3 The shares underlying the option were fully vested when transferred.